SCHEMBL128473

SCHEMBL128473

O=C1N=CNC1=Cc1c[nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
CYP2A6 P11509 1/20 0.50
IMPDH2 P12268 1/20 0.50
NTRK1 P04629 2/20 0.47
DAPK3 O43293 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
ABL1 P00519 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
CSF1R P07333 1/20 0.47
RET P07949 1/20 0.47
PDGFRB P09619 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128472 1.00 MAPT (0.50) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5003596 1.00 MAPT (0.50) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL3467529 0.73 NTRK1 (0.56) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL3467350 0.73 NTRK1 (0.56) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL3467353 0.73 NTRK1 (0.56) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5145062 0.72 NAT1 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2NFKB1
SCHEMBL16111817 0.72 NAT1 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2NFKB1
SCHEMBL3781740 0.71 LMNA (0.46) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL26425931 0.71 MEN1 (0.61) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL860566 0.70 KDM4E (0.49) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 US disclosed
US-20150309021-A1 Advanced Drug Development and Manufacturing LOS ALAMOS NATIONAL SECURITY, LLC 2015-10-29 US disclosed
EP-2511844-B1 X-ray microscope XRPRO SCIENCES INC (US) 2015-08-12 EP disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
US-8278120-B2 Method of changing fluorescence wavelength of fluorescent protein NEC SOFT, LTD. (JP) 2012-10-02 US disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
EP-1988161-B1 METHOD OF CHANGING FLUORESCENCE WAVELENGTH OF FLUOROPROTEIN NEC SOFTWARE LTD (JP) 2012-03-07 EP disclosed
US-20090318673-A1 METHOD OF CHANGING FLUORESCENCE WAVELENGTH OF FLUORESCENT PROTEIN NEC SOFT, LTD. (JP) 2009-12-24 US disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
EP-1988161-A1 METHOD OF CHANGING FLUORESCENCE WAVELENGTH OF FLUOROPROTEIN Nec Soft, LTD. (JP) 2008-11-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318673-A1 METHOD OF CHANGING FLUORESCENCE WAVELENGTH OF FLUORESCENT PROTEIN GPKOW, GLMN, FIBP MAPT 1814/4885MEN1 4142/4885KMT2A 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.